Omomyc enhances PARP inhibitor effects and overcomes resistance in breast cancer models

Findings from a preclinical study demonstrate that Omomyc—the only direct MYC inhibitor to have successfully completed a phase I clinical trial—causes DNA damage in cancer cells which is synergistically enhanced in combination with poly…

Continue Reading

News Source: medicalxpress.com